These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8745351)

  • 1. Docetaxel delivers new management opportunities for gastrointestinal carcinomas.
    Rougier P
    Anticancer Drugs; 1995 Jul; 6 Suppl 4():25-9. PubMed ID: 8745351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
    Dieras V; Chevallier B; Kerbrat P; Krakowski I; Roche H; Misset JL; Lentz MA; Azli N; Murawsky M; Riva A; Pouillart P; Fumoleau P
    Br J Cancer; 1996 Aug; 74(4):650-6. PubMed ID: 8761385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma.
    Pazdur R; Lassere Y; Soh LT; Ajani JA; Bready B; Soo E; Sugarman S; Patt Y; Abbruzzese JL; Levin B
    Ann Oncol; 1994 May; 5(5):468-70. PubMed ID: 7915537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group.
    Verweij J; Catimel G; Sulkes A; Sternberg C; Wolff I; Aamdal S; van Hoesel Q
    Eur J Cancer; 1995; 31A Suppl 4():S21-4. PubMed ID: 7577101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
    Catimel G; Verweij J; Mattijssen V; Hanauske A; Piccart M; Wanders J; Franklin H; Le Bail N; Clavel M; Kaye SB
    Ann Oncol; 1994 Jul; 5(6):533-7. PubMed ID: 7918125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.
    Fumoleau P; Chevallier B; Kerbrat P; Krakowski Y; Misset JL; Maugard-Louboutin C; Dieras V; Azli N; Bougon N; Riva A; Roche H
    Ann Oncol; 1996 Feb; 7(2):165-71. PubMed ID: 8777173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
    Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
    J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.
    ten Bokkel Huinink WW; Prove AM; Piccart M; Steward W; Tursz T; Wanders J; Franklin H; Clavel M; Verweij J; Alakl M
    Ann Oncol; 1994 Jul; 5(6):527-32. PubMed ID: 7918124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.
    Sulkes A; Smyth J; Sessa C; Dirix LY; Vermorken JB; Kaye S; Wanders J; Franklin H; LeBail N; Verweij J
    Br J Cancer; 1994 Aug; 70(2):380-3. PubMed ID: 7914428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Chevallier B; Fumoleau P; Kerbrat P; Dieras V; Roche H; Krakowski I; Azli N; Bayssas M; Lentz MA; Van Glabbeke M
    J Clin Oncol; 1995 Feb; 13(2):314-22. PubMed ID: 7844592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
    Piccart MJ; Klijn J; Paridaens R; Nooij M; Mauriac L; Coleman R; Bontenbal M; Awada A; Selleslags J; Van Vreckem A; Van Glabbeke M
    J Clin Oncol; 1997 Sep; 15(9):3149-55. PubMed ID: 9294478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of docetaxel (Taxotere) for untreated advanced colorectal carcinoma.
    Clark TB; Kemeny NE; Conti JA; Huang Y; Andre AM; Stockman J
    Cancer Invest; 1998; 16(5):314-8. PubMed ID: 9627678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.
    Mavroudis D; Kourousis C; Androulakis N; Kalbakis K; Agelaki S; Kakolyris S; Souglakos J; Sarra E; Vardakis N; Hatzidaki D; Sarmonis G; Georgoulias V
    Am J Clin Oncol; 2000 Aug; 23(4):341-4. PubMed ID: 10955859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [An early phase II clinical study of RP56976 (docetaxel) in patients with cancer of the gastrointestinal tract].
    Taguchi T
    Gan To Kagaku Ryoho; 1994 Oct; 21(14):2431-7. PubMed ID: 7944488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
    Trudeau ME; Eisenhauer EA; Higgins BP; Letendre F; Lofters WS; Norris BD; Vandenberg TA; Delorme F; Muldal AM
    J Clin Oncol; 1996 Feb; 14(2):422-8. PubMed ID: 8636752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group.
    Bruntsch U; Heinrich B; Kaye SB; de Mulder PH; van Oosterom A; Paridaens R; Vermorken JB; Wanders J; Franklin H; Bayssas M
    Eur J Cancer; 1994; 30A(8):1064-7. PubMed ID: 7654430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.
    Sternberg CN; ten Bokkel Huinink WW; Smyth JF; Bruntsch V; Dirix LY; Pavlidis NA; Franklin H; Wanders S; Le Bail N; Kaye SB
    Br J Cancer; 1994 Aug; 70(2):376-9. PubMed ID: 7914427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced head and neck cancer and clinical experience of an effective new agent: docetaxel.
    Schöffski P; Weihkopf T; Ganser A
    Anticancer Res; 1998; 18(6B):4751-6. PubMed ID: 9891552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan.
    Okada S; Sakata Y; Matsuno S; Kurihara M; Sasaki Y; Ohashi Y; Taguchi T
    Br J Cancer; 1999 May; 80(3-4):438-43. PubMed ID: 10408850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy.
    Lenzi R; Yalcin S; Evans DB; Abbruzzese JL
    Cancer Invest; 2002; 20(4):464-72. PubMed ID: 12094541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.